The notion that CSF β-glucocerebrosidase activity is reduced in PD patients independent of their GBA mutation carrier status suggests that GCase activity could be a valuable biomarker for idiopathic forms of PD and DLB and as an objective outcome measure in clinical trials13, and further studies are warranted. The gene discussed is GBA1; the disease is Parkinson disease.